2007年
An up-to-date anti-cancer treatment strategy focusing on HIF-1 alpha suppression: Its application for refractory ovarian cancer
ACTA HISTOCHEMICA ET CYTOCHEMICA
- 巻
- 40
- 号
- 5
- 開始ページ
- 139
- 終了ページ
- 142
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1267/ahc.07024
- 出版者・発行元
- JAPAN SOC HISTOCHEMISTRY & CYTOCHEMISTRY
Hypoxia inducible factor-1 alpha (HIF-1 alpha) predominantly determines the transcriptional activity of HIF-1, which induces the certain genetic expressions to participate in the proliferation and progression of the tumor. It is supposed that HIF-1 alpha is also an extremely important factor in cancer treatment. Based on the results of our recent analyses using ovarian tumors, which indicated the close association of HIF-1 alpha expression with the acquisition of malignancy and the characterization of histology, we further investigated the possibility of a new strategy of cancer therapy that targeted HIF-1 alpha inhibition in the ovarian carcinoma. The cell line HUOCA-II, which originates from the refractory ovarian clear cell adenocarcinoma, was treated with rapamycin. The inhibitory effect of HIF-1 alpha was analyzed by immunohistochemistry and western blotting. It was demonstrated that inhibition of HIF-1 alpha and vascular endothelial growth factor (VEGF) expressions would lead to the down-regulation of tumor cell proliferation. Interestingly, there was little or no change in GLUT-1 expression by rapamycin administration. Thus, the inhibition of GLUT-1 may also be a key for the new strategy of cancer therapy as well as HIF-1 alpha and VEGF.
- リンク情報
- ID情報
-
- DOI : 10.1267/ahc.07024
- ISSN : 0044-5991
- eISSN : 1347-5800
- PubMed ID : 18224245
- Web of Science ID : WOS:000251859100002